Quinn Opportunity Partners LLC Buys 125,000 Shares of Novavax, Inc. (NASDAQ:NVAX)

Quinn Opportunity Partners LLC grew its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 1,130.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,061 shares of the biopharmaceutical company's stock after buying an additional 125,000 shares during the period. Quinn Opportunity Partners LLC owned approximately 0.08% of Novavax worth $1,094,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in shares of Novavax by 33.7% in the third quarter. The Manufacturers Life Insurance Company now owns 79,783 shares of the biopharmaceutical company's stock valued at $1,008,000 after buying an additional 20,127 shares in the last quarter. State Street Corp lifted its position in shares of Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock worth $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Wellington Management Group LLP bought a new position in Novavax in the third quarter valued at about $923,000. Barclays PLC boosted its stake in shares of Novavax by 73.9% in the 3rd quarter. Barclays PLC now owns 709,579 shares of the biopharmaceutical company's stock valued at $8,961,000 after purchasing an additional 301,627 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Novavax by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company's stock worth $44,245,000 after purchasing an additional 304,159 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NVAX shares. TD Cowen upgraded shares of Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research began coverage on shares of Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $18.00.

Novavax Price Performance

Shares of NASDAQ NVAX traded down $0.32 during mid-day trading on Thursday, reaching $5.89. 2,453,564 shares of the company's stock were exchanged, compared to its average volume of 8,192,066. Novavax, Inc. has a 52 week low of $3.81 and a 52 week high of $23.86. The firm has a 50-day moving average price of $7.36 and a two-hundred day moving average price of $8.72. The firm has a market capitalization of $946.57 million, a price-to-earnings ratio of -2.61, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) EPS. As a group, sell-side analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.